Contact Supplier

Contact Supplier

To get in touch with TAmiRNA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    TAmiRNA presents innovative miRNA biomarker technologies to Japanese Pharma

    news-releasesTAmiRNA GmbH
    December 14th 2023

    Vienna, Austria: Biotech and diagnostic innovator TAmiRNA sent a top-level team to Japan to introduce its innovative transcriptomics technologies for microRNA biomarker development and Exosome drug characterizations to the country’s leading pharma companies.

    The team was headed by CEO/CSO Dr. Matthias Hackl and included fellow CFO Otto Kanzler and senior scientific advisors Dr. Johannes Grillari and Dr. Regina Grillari.

    Presenting miND pipeline

    During the week-long Japan tour from November 11 to November 18, TAmiRNA joined with local partner Summit Pharmaceutical International (SPI) to present its offerings to 12 medium-to-large-size pharmaceutical companies.  Presentations from Dr. Hackl included information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs for enhanced analysis.

    In addition, Dr. Hackl co-hosted an SPI-organized seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products”, attended by more than 70 Japanese life sciences professionals from industry and academia.

    In his talk, Matthias explained the advantages and value of TAmiRNA’s full molecular characterization of exosomes and extracellular vesicles (EVs) to determine the molecular composition of extracellular vesicles and its association to EV mode-of-action.

    About TAmiRNA

    TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality biomarker and drug discovery research.

    TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

    For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

    More information available at:

    About SPI

    Summit Pharmaceutical International (SPI) is a core operating company in the Medical Science Business Unit of the Sumitomo Corporation Group. SPI’s mission is to contribute to enriching lives and the world through improvement of health and well-being by linking pharmaceutical companies in Japan and overseas, leveraging its global network and expertise.

    SPI’s key businesses include Import, export, and marketing of drugs, quasi-drugs, medical devices, and food additives, as well as materials, bulks, and final products, Import and marketing of microbial, plant and animal cells and tissues and analytical devices as drug discovery support tools, as well as brokerage and mediation of related biological services, along with consulting and mediation activities to support pharma development and new drug licensing.

    The company’s workforce currently numbers almost 160 people and in 2022/23 it recorded sales exceeding 40 bn yen (USD 272.4m).

    Learn more at:


    Click on TAmiRNA microRNA biomarkers to learn more.
    Click on TAmiRNA MiND Next Generation Sequencing  for further information.
    Click on TAmiRNA one-stop-shop characterization of extracellular vesicles (EVs) and exosomes for further information.


    hepatomiR® is a blood-based Biomaker for the Assessment of Live Function before Hepatectomy in patients with HCC, CCC or mCRC

    TAmiRNA presents innovative miRNA biomarker technologies to Japanese Pharma

    TAmiRNA founding team (rear from left) Drs. Johannes and Regina Grillari, CFO Otto Kanzler and CEO/CSO Dr. Matthias Hackl with Japanese partners from Summit Pharmaceutical International.

    TAmiRNA presents innovative miRNA biomarker technologies to Japanese Pharma

    Contact TAmiRNA GmbH

    Simply fill out the form below to contact TAmiRNA GmbH now.

    Send TAmiRNA GmbH a Message